Crispr Therapeutics Company Insiders
| CRSP Stock | USD 41.59 0.45 1.07% |
Crispr Therapeutics employs about 407 people. The company is managed by 18 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 22.61 employees per reported executive. Discussion of Crispr Therapeutics' management performance can provide insight into the enterprise performance.
| Samarth Kulkarni Executive Chief Business Officer |
| James Kasinger Director General Counsel, Secretary to the Board of Directors |
Crispr |
Crispr Therapeutics' latest congressional trading
Congressional trading in companies like Crispr Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Crispr Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2021-01-15 | Senator James Inhofe | Acquired Under $15K | Verify |
Crispr Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0957) % which means that it has lost $0.0957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1307) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Crispr Therapeutics Workforce Comparison
Crispr Therapeutics AG is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 89,959. Crispr Therapeutics adds roughly 407 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (1.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (182.94) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $182.94. Crispr Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Crispr Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Crispr Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Crispr Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Samarth Kulkarni over a month ago Disposition of 23121 shares by Samarth Kulkarni of Crispr Therapeutics at 55.43 subject to Rule 16b-3 | ||
Samarth Kulkarni over a month ago Disposition of 13751 shares by Samarth Kulkarni of Crispr Therapeutics at 16.21 subject to Rule 16b-3 | ||
Samarth Kulkarni over three months ago Disposition of 20000 shares by Samarth Kulkarni of Crispr Therapeutics at 19.12 subject to Rule 16b-3 |
Crispr Therapeutics Notable Stakeholders
A Crispr Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Crispr Therapeutics often face trade-offs trying to please all of them. Crispr Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Crispr Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shaun CFA | Founder | Profile | |
| James Kasinger | General Counsel, Secretary to the Board of Directors | Profile | |
| Samarth Kulkarni | Chief Business Officer | Profile | |
| James JD | General Secretary | Profile | |
| Susan Kim | Vice Relations | Profile | |
| Craig Mello | Scientific Member | Profile | |
| Lawrence Klein | Chief Officer | Profile | |
| Chad Cowan | Scientific Founder | Profile | |
| Rodger MD | Chairman Founder | Profile | |
| Daniel Anderson | Scientific Member | Profile | |
| Emmanuelle Charpentier | CoFounder Member | Profile | |
| Raju Prasad | Chief Officer | Profile | |
| Matthew MD | Scientific Member | Profile | |
| Stephen Kennedy | Head Operations | Profile | |
| Julianne MBA | Chief Officer | Profile | |
| Brendan MBA | CFO VP | Profile | |
| MD FACP | Chief Officer | Profile | |
| Shaun Foy | Founder | Profile |
About Crispr Therapeutics Management Performance
The success or failure of an entity such as Crispr Therapeutics often depends on how effective the management is. Crispr Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Crispr management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Crispr management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics is traded on NASDAQ Exchange in the United States.
Crispr Therapeutics Workforce Analysis
Traditionally, organizations such as Crispr Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Crispr Therapeutics within its industry.Crispr Therapeutics Manpower Efficiency
Return on Crispr Therapeutics Manpower
| Revenue Per Employee | 912.1K | |
| Revenue Per Executive | 20.6M | |
| Net Loss Per Employee | 377.4K | |
| Net Loss Per Executive | 8.5M | |
| Working Capital Per Employee | 4.4M | |
| Working Capital Per Executive | 100M |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.